CLOV insider RSU vesting leads to 71,432-share tax withholding

Rhea-AI Filing Summary

Clover Health Investments, Corp. (CLOV) reported an insider transaction on a Form 4. Officer Jamie L. Reynoso (CEO, Medicare Advantage) had 71,432 shares of Class A Common Stock automatically withheld on 10/15/2025 to cover taxes from RSU vesting, at a transaction price of $2.8 per share (Code F).

Following this tax withholding, the insider beneficially owns 2,971,740 shares, held directly. The RSUs were granted on 10/15/2024; 25% vested on 10/15/2025. The remaining RSUs vest quarterly in equal 6.25% installments through 10/15/2028, subject to continued service.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Reynoso Jamie L.

Role CEO, Medicare Advantage

Type	Security	Shares	Price	Value
Tax Withholding	Class A Common Stock	71,432	$2.80	$200K

Holdings After Transaction: Class A Common Stock — 2,971,740 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Reynoso Jamie L.

(Last) (First) (Middle)

C/O CLOVER HEALTH INVESTMENTS, CORP.

NOT APPLICABLE

(Street)

WILMINGTON DE 19801

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
CLOVER HEALTH INVESTMENTS, CORP. /DE [ CLOV ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CEO, Medicare Advantage

3. Date of Earliest Transaction (Month/Day/Year)
10/15/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Common Stock	10/15/2025		F		71,432(1)	D	$2.8	2,971,740	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares of Class A Common Stock that were automatically withheld to cover tax obligations on October 15, 2025, due to the vesting of 25% of the original number of restricted stock units (RSUs) granted to the Reporting Person on October 15, 2024, and timely reported on a Form 4 filed on October 17, 2024. The remaining RSUs vest quarterly in equal installments of 6.25%, with the final vesting date occurring on October 15, 2028, subject to the continued service of the Reporting Person on each such vesting date.

Remarks:

	/s/Peter J. Rivas as attorney-in-fact for Jamie L. Reynoso	10/17/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did CLOV disclose in this Form 4?

An officer had 71,432 Class A shares withheld on 10/15/2025 to cover taxes from RSU vesting at $2.8 per share (Code F).

Who is the reporting person in CLOV's Form 4?

The reporting person is Jamie L. Reynoso, an officer titled CEO, Medicare Advantage.

How many CLOV shares does the insider own after the transaction?

Beneficial ownership after the transaction is 2,971,740 shares, held directly.

What triggered the share withholding for CLOV?

The withholding covered tax obligations arising from RSU vesting on 10/15/2025.

What is the vesting schedule for the CLOV RSUs?

25% vested on 10/15/2025; the remainder vests quarterly in 6.25% installments through 10/15/2028, subject to continued service.

Was this an open-market sale of CLOV shares?

No. It was a tax withholding (Transaction Code F) related to RSU vesting.

Does the filing mention a trading plan under Rule 10b5-1?

The filing includes standard instructions, but the disclosed transaction is a withholding for taxes tied to RSU vesting.